Polyclonal localized light chain amyloidosis - a distinct entity?
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Aishwarya Ravindran, Karen L. Grogg, David A. Domaas, Ronald S. Go (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O’Brien, Hagop Kantarjian, Farhad Ravandi We reviewed 301 patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) who presented from January 2000 to January 2014 (183, t-AML without antecedent hematologic disorders [AHD]; 118, t-AML with AHD). Overall, median follow-up was 44 months. The primary malignancy was non-Hodgkin lympho...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Myelomatous Involvement of the Central Nervous System
Conclusion Myelomatous involvement of the CNS is a rare complication that portends poor survival. Current therapeutic approaches appear to be largely ineffective in this subset of myeloma patients. Teaser Myelomatous involvement of the central nervous system (CNS) is an uncommon complication that portends a poor prognosis in patients with multiple myeloma (MM). Limited data exist regarding optimal management of CNS myeloma. In this case-control study, we examine the clinical presentation, diagnosis, treatment and outcomes of CNS myeloma patients compared with a control group of MM patients without CNS involvement, matched ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Single-Center Series of Bone-Marrow Biopsy-Defined Large Granular Lymphocyte leukemia; high rates of sustained response to oral methotrexate
Conclusion. Single agent oral methotrexate appears to be highly efficacious, resulting in long response durations accompanied by minimal toxicity. Teaser 39 patients were stringently diagnosed with large granular lymphocyte leukemia. 15 (38%) remain untreated, 13/24 initially treated with prednisolone, overall response rate (ORR) 84.6%, median duration of response (DOR) 13.5 months, 9/24 received oral methotrexate ORR 89%, median DOR 132.7 months. Five received methotrexate following prednisolone failure; all responded. Single agent oral methotrexate results in long responses with minimal toxicity. (Source: Clinical Lympho...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Conclusion Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor-stage and folliculotropic mycosis fungoides. Teaser Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Indolent Lymphomas that Present with Clinically Aggressive Features: A Subset of Low Grade Lymphomas with a Behavior Inconsistent with the Histologic Diagnosis
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): F. Cabanillas, N. Rivera, W.I. PardoTeaser We have identified a subset of indolent lymphoma whose presentation differs from their expected indolent nature. They present with aggressive features such as high LDH, high SUVs, high Ki-67 (>30%), B symptoms, unusual areas of involvement (bone, pleura, lung). In spite of the fact that histologically they resemble typical indolent NHLs, they functionally behave as aggressive NHLs. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Evaluation of the impact of renal failure on correlation and concordance between two free light chain assays
Conclusions Despite adjusted reference ranges for FreeliteTM FLC ratio, there remains about ≈12.5% discrepancies in interpretation of FLC ratio between the two available assays. They are not linked to renal failure stage and neither of the assays performed better than the other: results must be interpreted taking into account clinical data and the same assay must be used for patient’s follow-up. Teaser Measurement of serum free light chains (FLC) is recommended for diagnosis of monoclonal gammopathies. FLC measurements with FreeliteTM (Binding Site) and N-Latex FLC (Siemens) assays were performed on 1215 fresh ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

The T cell in Myeloma
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Douglas Joshua, Hayley Suen, Ross Brown, Christian Bryant, P Joy Ho, Derek Hart, John Gibson An active role for the immune system in controlling the malignant plasma cell clone in myeloma has been postulated for many years. The clinical states of monoclonal gammopathy of undetermined significance, plateau phase disease and smoldering myeloma all suggest that a significant host-tumor interaction is taking place. The fundamental role of the cytotoxic T cell in tumor elimination and control has been exemplified by the d...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Aberrant p15, p16, p53 and DAPK gene methylation in myelomagenesis: clinical and prognostic implications
Conclusion The current study supports a relevant role for p15, p16 and DAPK hypermethylation in the genesis of the plasma cell neoplasm. DAPK hypermethylation might also be an important step in the progression from MGUS to MM. Teaser Microabstract: Aberrant DNA methylation is important in multiple myeloma pathogenesis. Methylation of p15, p16, p53 and DAPK genes was evaluated in bone marrow (94 patients; 8 controls) by methylation-specific polymerase chain reaction. 63% of MM and 39% of MGUS presented ≥1 hypermethylated gene (p<0.05). This supports a relevant role for hypermethylation in the pathogenesis of the p...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

An Evaluation of Treatment Patterns and Outcomes in Newly Diagnosed Elderly Acute Myeloid Leukemia Patients: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices
Conclusions As expected, OS in patients receiving low-intensity therapy or BSC with HU is poor for elderly AML patients. Remarkably, intensive induction strategies are rarely used for older patients in community oncology practice. Teaser MicroAbstract: This retrospective observational study of data from the US community oncology setting evaluates real-world treatment patterns and outcomes for newly diagnosed, elderly patients with acute myeloid leukemia (AML). The analysis focuses on those patients who did not receive standard induction therapy (‘3 + 7’ type regimens). (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Significance of The Cereblon Expression in Multiple Myeloma Patients
Conclusion CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as immunomodulatory drug. Indicating possible suboptimal treatment outcome, the level of CRBN expression may serve as additional prognostic tool in personalized treatment approach. Teaser Within a personalized treatment approach in multiple myeloma (MM), prognostic significance of the cereblon (CRBN) expression was analysed in 92 newly diagnosed patients. In patients treated with thalidomide based combinations, CRBN expression significantly affected treatment response (p=0.028), and progression free survival (PFS, ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Survival rates of adults with acute lymphoblastic leukemia in a low- income population. A decade of experience at a single institution in M éxico
Conclusion Adults with ALL in Mexico had high-risk characteristics and increased relapse rate, however OS after CR was similar to the highest achieved in developed countries, suggesting that a threshold for curing adult ALL with current therapeutic strategies has been reached. Teaser Adult acute lymphoblastic leukemia has an elevated mortality rate, with little improvement in recent decades. 94 patients treated over ten years in a low-income population were studied. Younger age, elevated high-risk disease and high relapse rate were documented. However, overall survival after complete remission was the same as in industrial...
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Vorinostat in Combination with Lenalidomide and Dexamethasone in Lenalidomide Refractory Multiple Myeloma
Conclusion These observations demonstrate that the addition of vorinostat to patients with lenalidomide and dexamethasone refractory multiple myeloma was associated with moderate response and was well tolerated warranting further assessment in a larger prospective study. Teaser Lenalidomide/dexamethasone refractory patients were treated with the combination of lenalidomide, dexamethasone and vorinostat. An ORR of 27% was seen and therapy was well tolerated. This represents a treatment option in heavily pretreated myeloma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 10, 2016 Category: Cancer & Oncology Source Type: research

Clinical Skin Cancer: The Next Addition to Elsevier's Clinical Cancer (ECC) Journal Portfolio
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 8 (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 9, 2016 Category: Cancer & Oncology Source Type: research

Bone Marrow Necrosis: An Unusual Initial Presentation of Sickle Cell Anemia
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Georges El Hachem, Nabil Chamseddine (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States
We report our experience with adult T-cell leukemia/lymphoma, a rare and aggressive form of T-cell lymphoma, highlighting the clinical characteristics, response to therapy, and outcomes. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma
Conclusion Detection of cell-free plasma EBV-DNA was highly concordant with the presence of EBERs in tumor tissue, predicted survival independent of LDH and LCT, and should be further studied as a biomarker in AS CTCL. Micro-Abstract Discovering prognostic factors that simultaneously describe tumor characteristics and improve risk stratification is a priority in cutaneous T-cell lymphoma (CTCL). More than a third of advanced stage CTCL patients in this cohort had detectable cell free plasma Epstein–Barr virus (EBV)-DNA (pEBVd) using quantitative real-time polymerase chain reaction. An increased level of pEBVd was hig...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience
Conclusions Given its rarity, our knowledge of PEL relies solely on case reports and case series. Prompt HAART and chemotherapy may be effective in HIV- associated PEL and good outcomes are possible. LDH and CD4 may be possible prognostic factors in PEL. Micro-Abstract Primary effusion lymphoma (PEL) is a rare form of lymphoma, primarily seen in individuals who are immunosuppressed. We studied all cases of PEL seen at our institution over a 15-year period and observed that if affected mostly male patients with HIV who were not taking the antiretroviral medication. Newer chemotherapy regimens including the drug bortezomib m...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature
Conclusions LYG is a rare B-cell lymphoproliferative disorder with involvement if the respiratory system. The presentation is heterogeneous, and response to therapy is variable. Although it is considered a poor prognosis disease, long-term survivors in remission have been described. Micro-Abstract Lymphomatoid granulomatosis is a rare B-cell lymphoproliferative disorder characterized by involvement of the respiratory system and frequently associated with EBV infection. In this study we present the general characteristics in a single institution. Treatment with rituximab based-chemotherapy was effective with long term respo...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Human Herpesvirus Type 8-positive Multicentric Castleman Disease
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Anait L. Melikyan, Elena K. Egorova, Hunan L. Julhakyan, Alla L. Kovrigina, Valeriy G. Savchenko Castleman disease (CD) is rare lymphoproliferative disorder with local lesionsor with multiple lessions (multicentric CD [MCD]–usually with plasma cell or mix cell morphology). Patients with human herpesvirus (HHV) type 8-positive MCD were included in a separate group owing to its extremely aggressive course and the high risk of transformation into HHV8+ plasmablastic lymphoma. At our hematologic center, from 199...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload
Conclusion Elevated serum ferritin levels might predict poorer survival in autoHSCT recipients. Micro-Abstract Transfusional iron overload (IO) is considered to be a significant problem hematopoietic stem cell transplantation (HSCT) recipients. Patients with IO have poorer outcomes compared to those with normal iron stores. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Georges El Hachem, Nabil Chamseddine, Ghada Saidy, Camil Choueiry, Claude Afif (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Is Maintenance Therapy for Everyone?
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Ajay K. Nooka, Sagar Lonial Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review ai...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

How to Think About Risk in Myeloma
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Amrita Krishnan An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are “risk...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Clonal Evolution in Multiple Myeloma
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Bita Fakhri, Ravi Vij Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the result of an empiric research paradigm. However, with the application of next genera...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): John Mascarenhas Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape of MPN-BP is distinct from de novo acute myeloid leukemia and offers insight into molecular mechanisms contributing to clonal evolution providing potential novel drug targets. A number of retrospective studies have identified patient- and disease-specific variables associated with increased risk of leukemic transformatio...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

How to Treat Essential Thrombocythemia and Polycythemia Vera
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Carlos Besses, Alberto Alvarez-Larrán Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive th...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Prognosis of Primary Myelofibrosis in the Genomic Era
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Prithviraj Bose, Srdan Verstovsek Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and re...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

When to Consider Allogeneic Transplantation in CML
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Jerald Radich Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Conclusion These findings suggest that dasatinib therapy (within the therapeutic range) can increase trabecular bone, without causing significant changes in bone and mineral metabolism. Nonetheless, monitoring of bone health and skeletal integrity should be included into the long-term management of patients treated with dasatinib to further enhance our understanding of its safety profile and its potential role as a treatment modality for other bone diseases. Micro-Abstract We assessed patients with chronic myelogenous leukemia for serum Ca, PO4, bone alkaline phosphatase, N-telopeptide, osteoprotegerin levels and trabecula...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome –Positive Chronic Myeloid Leukemia
Conclusion Most imatinib-intolerant patients develop blastic phase transformation, with a poor survival of 3 to 6 months; no effective rescue treatment is available. Future research should to determine whether the origin of this evolution is really due to the intolerance itself or whether it is due to a more aggressive form of the disease, perhaps related to genetic transformation. Micro-Abstract The overall prognosis of Philadelphia chromosome–positive chronic myeloid leukemia patients is today considered to be good thanks to targeted therapy with tyrosin kinase inhibitors (TKIs). A study of a 86-patient cohort show...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Emili Montserrat, Peter Dreger The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adver...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Conclusion These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS. Micro-Abstract PDE4 expression control the inflammation which has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). The expression of each isoform of the PDE4 was evaluated, using transcriptomic profiling, from healthy individuals (n = 10) and patients with MDS (n =...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Conclusion Further clinical studies are needed to identify patients with CMML who will benefit from this treatment. Micro-Abstract In a phase I dose-escalation study using eltrombopag to treat patients with myelodysplastic syndromes after hypomethylating agents failure, we observed that patients with chronic myelomonocytic leukemia may respond to eltrombopag. However, use in a subset of chronic myelomonocytic leukemia patients may be limited owing to leukocytosis and circulating blasts. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Trends in Clinical Investigation for Myelodysplastic Syndromes
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Thomas Prebet, Amer Zeidan Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are ava...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Conclusion MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. Micro-Abstract Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation o...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Asmita Mishra, Claudio Anasetti Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Conclusion IST has a hematologic improvement response rate in the range of other therapies approved for lower risk MDS. High risk IPSS-R, poor karyotype, and treatment after 2 years from diagnosis have unfavorable response trend. ATG with CSA has higher response than ATG alone. First-line ATG or after lenalidomide had better response trend compared to third-line therapy or azacitidine therapy. Micro-Abstract Immunosuppresive therapy in low risk myelodysplastic syndrome can achieve sustained hematologic improvement but is underutilized due to lack of selection criteria. We completed a retrospective analysis of sixty-six pat...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Rami S. Komrokji The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT)...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing  Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AML and MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%). Quantitative reverse transcriptase-polymerase chain reaction analysis of 8 AML and 11 low-grade (LG)-MDS cases confirmed that HDM4 and HDM4-S mRNA expression were also elevated in all AML cases. HDM4 and HDM4-S mRNA expression was...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Nicholas J. Short, Farhad Ravandi Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia
Conclusion There is a significant correlation between some markers, and certain ALL recurrent cytogenetic subgroups (CD123 and hyperdiploidy, CD79b negativity, and ETV-RUNX1 group) have good prognostic value. CD200 can be used as MRD markers in ALL patients and can also can serve as therapy targets. Micro-Abstract ALL is the most common childhood malignancy and identification of prognostic factors is important for further improvement of the treatment outcome in this fatal disease. Cytogenetic changes and MRD are the most powerful prognostic factors in ALL. We identified significant correlations between some CD markers and ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Conclusion Hepatic iron content might be associated with poorer prognosis in patients with iron overload that underwent alloHSCT. Micro-Abstract Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Perspectives and Future Directions for Acute Lymphoblastic Leukemia
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Anjali S. Advani (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Stephanie A. Folan, Amber Rexwinkle, Jane Autry, Jeffrey C. Bryan Adult patients with acute lymphoblastic leukemia who relapse after frontline therapy have extremely poor outcomes despite advances in chemotherapy and hematopoietic stem cell transplantation. Blinatumomab is a first-in-class bispecific T-cell engager that links T cells to tumor cells leading to T-cell activation and tumor cell lysis. In December 2014, the Food and Drug Administration approved blinatumomab for treatment of relapsed or refractory Phil...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Alan F. List, Hagop Kantarjian, Emil J. Freireich (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia
Conclusion AlloHCT2 remains a potential curative option in a subset of patients with relapsed ALL after the first AlloHCT. Micro-Abstract The outcome of patients with acute lymphoblastic leukemia relapsing after first allogeneic hematopoietic cell transplantation remains poor. A second transplant is a potential curative option for a subset of patients. Patients with relapse within the first year after allogeneic hematopoietic cell transplantation should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Continued Role of Splenectomy in the Management of Patients With Myelofibrosis
Publication date: Available online 8 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Daniel Aruch, Myron Schwartz, John Mascarenhas, Marina Kremyanskaya, Carrie Newsom, Ronald Hoffman (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Conclusion NK cell counts after allo-HSCT, especially on day 30, were predictive of acute graft-versus-host disease, nonrelapse mortality, and survival. Serial lymphocyte subset analysis can be used to identify and treat patients at risk during the early period after allo-HSCT. Micro-Abstract Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed the data from 70 patients who had undergone allo-HSCT with the lymphocyte subset results. Also, the association between the lymphocyte subset counts and early compli...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
Conclusion Elderly patients aged < 75 years were able to tolerate standard immunochemotherapy, with acceptable survival profiles. In an Asian population, 75 years seems to be a judicious cutoff for predicting treatment outcomes. Micro-Abstract We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged > 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients < 75 years old tolerated standard immunochemotherapy, with acceptable survival p...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research